At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 438 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Plaque Psoriasis. Completed, enrolled 438 participants across 17 sites.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartApr 2018
Primary CompletionJun 2020
TodayJul 2026
First PostedDec 6, 2017
Enrollment StartApr 26, 2018
Primary CompletionJun 4, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.6 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC